
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is well-positioned for growth in the pharmaceutical industry with its differentiated products and strong commercial capabilities. The recent reverse stock split eliminates any potential delisting risk and increases the company's per share value, while also allowing for a higher terminal rate of decline. This aligns with the analyst's Buy rating and revised price target of $35, reflecting the company's potential for continued success in the long-term.
Bears say
Assertio Hldgs is facing significant challenges, as evidenced by the divestiture of its non-Rolvedon assets to Cosette for a relatively low valuation, indicating a lack of competitive interest. Its recent acquisition by Garda Therapeutics, while at a premium, also reflects the company's limited upside potential. Additionally, the company's loss on impairment of intangible assets and low revenue from its legacy products further support a negative outlook.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares